-
Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021
in PRESS RELEASE 2021 onFerring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer.
0 -
Fertility House Calls Now Available Nationwide to Help Women and Couples Take the First Steps to Parenthood Virtually
in PRESS RELEASE 2021 onFerring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer.
-
Women in India are the first in the world to receive new heat-stable carbetocin formulation to prevent excessive bleeding after childbirth
in PRESS RELEASE 2021 onFerring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer.
-
Ferring Pharmaceuticals announces changes to Board of Directors
in PRESS RELEASE 2021 onFerring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer.
-
Ferring presents new data at ESHRE 2021 supporting the use of Rekovelle® (follitropin delta) for individualized fertility treatment
in PRESS RELEASE 2021 onFerring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer.
-
Ferring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study of Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
in PRESS RELEASE 2021 onFerring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer.
-
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
in PRESS RELEASE 2021 onFerring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer.
-
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. Difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties
in PRESS RELEASE 2021 onFerring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer.
-
Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) 2021
in PRESS RELEASE 2021 onFerring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer.
PRESS RELEASE 2021
PRESS RELEASE 2021
